The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

The administration of antibodies blocking the immune checkpoint molecules programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) has evolved as a very promising treatment option for cancer patients. PD-1/PD-L1 inhibition has significantly enhanced expansion, cytokine secr...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Med
Main Authors: Tunger, Antje, Sommer, Ulrich, Wehner, Rebekka, Kubasch, Anne Sophie, Grimm, Marc-Oliver, Bachmann, Michael Philipp, Platzbecker, Uwe, Bornhäuser, Martin, Baretton, Gustavo, Schmitz, Marc
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2019
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6832659/
https://ncbi.nlm.nih.gov/pubmed/31557787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm8101534
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares